Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trialJean‐Michel Molina, Juergen Rockstroh, Ming‐Tain Lai et al.|The Lancet HIV|2018Cited by 145
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trialsChloe Orkin, Christine Katlama, Jean‐Michel Molina et al.|The Lancet HIV|2023Cited by 31
Dangers of Herpesvirus Infection in SLE Patients Under Anifrolumab Treatment: Case Reports and Clinical ImplicationsMads Lamm Larsen, Mads Nyhuus Bendix Rasch, Morten Kelder Skouboe et al.|American Journal of Case Reports|2024Cited by 9